| ||||||||||||||||||||||||||||||||||||||||||||||||
Swiss pharmaceutical1 giant Roche has said it will buy maker2 of lung disease therapies InterMune for $8.3bn.
瑞士医药巨头罗氏集团将要以83亿美元的价格收购肺部疾病药品生产商InterMune。
Intermune, which is based in Brisbane, California, makes a medicine for idiopathic(先天的) pulmonary fibrosis(肺纤维化), a deadly disease which scars the lungs.
It is also the largest by Roche since 2009 when it bought the remainder of Genentech for about $47bn.
Pharmaceutical mergers
Roche will pay $78 per share in InterMune, which is a premium5 of 38% on top of the value of the shares at the end of last week.
Recent deals in the drug sector include US drug firm AbbVie's purchase of the UK pharmaceutical company Shire for £32bn.
UK High Street chemist Alliance Boots was bought up by US pharmacy6 giant Walgreens in an agreement earlier this month.
In May, pharmaceutical company Pfizer dropped a bid for UK company AstraZeneca.
点击收听单词发音
|
||||||||||||||||||||||||||||||||||||||||||||||||
上一篇:欧盟对菜农果农进行资金补贴 下一篇:法国经济部长将离职 |
- 发表评论
-
- 最新评论 进入详细评论页>>